| Quantity | 500 µ, g, 1 mg, 5 mg, 10 mg | 1 mg, 5 mg, 10 mg | 250 mg, 500 mg, 1 g | 1 mg, 5 mg, 10 mg | 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |
| Description | Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative[1]. Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) | α-Helical CRF(9-41) is a competitive CRF2 receptor antagonist with KB of ~100 nM. α-Helical CRF(9-41) is also a partial agonist of CRF1 receptor with an EC50 of 140 nM[1][2] | Hemoglobin is a iron-containing protein in red blood cells with oxygen binding properties. Hemoglobin consits of heme, which binds to oxygen. Hemoglobin also transports other gases, such as carbon dioxide, nitric oxide, hydrogen sulfide and sulfide. Hemoglobin absorbs unneeded oxygen in tissues, as Hemoglobin is a iron-containing protein in red blood cells with oxygen binding properties. Hemoglobin consits of heme, which binds to oxygen. Hemoglobin also transports other gases, such as carbon dioxide, nitric oxide, hydrogen sulfide and sulfide. Hemoglobin absorbs unneeded oxygen in tissues, as an antioxidant[1]... Read More | M1145, a chimeric peptide, is a selective galanin receptor type 2 (GAL2) agonist, with a Ki of 6.55 nM. M1145 shows more than 90-fold higher affinity for GAL2 over GAL1 (Ki=587 nM) and a 76-fold higher affinity over GalR3 (Ki=497 nM). M1145 has an additive effect on the signal transduction of M1145, a chimeric peptide, is a selective galanin receptor type 2 (GAL2) agonist, with a Ki of 6.55 nM. M1145 shows more than 90-fold higher affinity for GAL2 over GAL1 (Ki=587 nM) and a 76-fold higher affinity over GalR3 (Ki=497 nM). M1145 has an additive effect on the signal transduction of galanin[1]... Read More | Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake[1]... Read More |